GBG Research presented at ASCO 2020


GBG Research presented at ASCO 2020

Data on several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Virtual Meeting 2020, which will take place from 29 to 31 May 2020.

Oral presentation #502
Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
Denkert C, Lambertini C, Fasching PA, et al.
Session: Oral Abstract Session / Breast Cancer—Local/Regional/Adjuvant
Speaker: Carsten Denkert

Poster discussion #516
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).
Moebus V, Lueck HJ, Ladda al.
Session: Poster Discussion Session / Breast Cancer—Local/Regional/Adjuvant
Speaker: Volker Möbus

Poster #580
Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy.
Wimberger P, Blohmer J-U, Krabisch P, et al.
Session: Poster Session / Breast Cancer—Local/Regional/Adjuvant

Poster #567
Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer patients: A transSENTINA analysis.
Kolberg HC, Kühn T, Krajewska M, et al.
Session: Poster Session / Breast Cancer - Local/Regional/Adjuvant


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd